ThromboGenics Presenting New Ophthalmic Research Data

- END - 

* Retina Consultants of Arizona, Phoenix, AZ 
  USC Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 

For further information please contact: 

    ThromboGenics                                     Citigate Dewe Rogerson
    Wouter Piepers,                                   David Dible/Sylvie Berrebi
    Global Head of Corporate Communications & IR      Tel: +44 20 7282 9571
    +32 16 75 13 10 / +32 478 33 56 32                david.dible@citigatedr.co.uk
    wouter.piepers@thrombogenics.com                  sylvie.berrebi@citigatedr.co.uk

About ThromboGenics  

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease.

The company's attractive pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market, diabetic retinopathy and diabetic macular edema.

ThromboGenics is conducting a Phase II clinical trial to assess THR-409 (ocriplasmin) as a potential treatment for non-proliferative diabetic retinopathy. THR-317, a neutralizing PIGF mAb being developed for the treatment of diabetic macular edema is expected to enter the clinic by end of 2016.

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, lead compound from a library of integrin antagonists, in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Alcon (Novartis) commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at http://www.thrombogenics.com

Important information about forward-looking statements 

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. 

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

SOURCE ThromboGenics